While it has been thought that cytokines (secreted signalling molecules) such as interleukin-4 or interleukin-13 have a critical role in onset and development of clinical asthma for some 20 years, confirmatory evidence has until now been lacking.
Dr Malinda Longphre, Aerovance Inc, Berkeley, California, USA and colleagues did two separate phase two clinical trials, in which patients with asthma were given pitrakinra. In study one, 12 patients were given 25mg pitrakinra by subcutaneous injection once daily, while a further twelve were given placebo. In the second study, 16 patients received either 60mg pitrakinra twice daily by nebulisation, while a further 16 were given placebo. The patients in each study inhaled allergens before and four weeks after treatment (known as ‘allergen challenge’, which induces an asthma attack).
Allergen inhalation causes an allergic reaction in the lungs which reduces their capacity to expel air. The primary endpoint for study one was maximum percentage decrease in forced expiratory volume (FEV1)** in one second over 4-10 hours after allergen challenge, whereas in study two it was average percentage decrease in FEV1 over 4-10 hours after allergen challenge. Smaller decreases in FEV1 during the asthma attack for the pitrakinra group versus placebo would mean that the allergic response had been decreased by pitrakinra.
The researchers found that in study one, the maximum percentage decrease in FEV1 was 17.1% in the pitrakinra group and 23.1% in the placebo group – a relative difference of 26%. In study two, the average percentage decrease in FEV1 was 4.4% in the pitrakinra group compared with 15.9% in the placebo group – (more than 3 and half times less in the pitrakinra group).
The authors conclude: “The effects of pitrakinra on late phase asthmatic response are promising when compared with similar studies with other successful anti-inflammatory asthma therapies…..whether the effect is due to inhibition of interleukin-13 alone, or both interleukin-13 an interleukin-4, is not yet known. Future studies of this drug, as well as molecules that specifically inhibit interleukin-13, in asthmatic individuals of all levels of severity over longer periods of time are clearly warranted.”
In an accompanying Comment, Dr Patrick Holt and Dr Peter Sly, Telethon Institute for Child Health Research, University of Western Australia, Subiaco, Western Australia, Australia, say: “These latest findings with pitrakinra are exciting and novel, and will breathe new life into the debate surrounding the role of the Th2-cytokine cascade in asthma pathogenesis and how best to design drugs to attenuate their effects.”
Tony Kirby | alfa
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine